Outcomes of Second-Line (2L) Triplet+ Regimens in Patients with Relapsed/Refractory Multiple Myeloma (MM) Following Progression after First-Line (1L) Lenalidomide in the Connect® MM Disease Registry
| Autor: | Lee, Hans C., Abonour, Rafat, Ailawadhi, Sikander, Durie, Brian G.M., Gasparetto, Cristina J., Hardin, James W. *, Narang, Mohit *, Omel, James *, Rifkin, Robert M., Terebelo, Howard *, Toomey, Kathleen *, Wagner, Lynne I. *, Slaff, Samantha *, Danforth, Dailan *, Chung, Weiyuan *, Anand, Jasmeet *, Yu, Edward *, Tang, Derek *, Jagannath, Sundar |
|---|---|
| Zdroj: | In Blood 15 November 2022 140 Supplement 1:13256-13258 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|